Aclaris Therapeutics (ACRS) Tops Q3 EPS by 9c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q3 EPS of ($0.30), $0.09 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $19.02 million versus the consensus estimate of $1.62 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Nike names former Pfizer CFO David Denton as new finance chief
• William Blair Upgrades Backblaze Inc (BLZE) to Market Perform